{"id":36306,"date":"2025-10-17T10:58:24","date_gmt":"2025-10-17T03:58:24","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=36306"},"modified":"2025-10-17T10:58:24","modified_gmt":"2025-10-17T03:58:24","slug":"a-d-a-m-innovations-and-sophia-genetics-partner-to-advance-liquid-biopsy-testing-and-companion-diagnostics-for-precision-oncology-in-japan","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=36306","title":{"rendered":"A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ROLLE, Switzerland\u00a0and TOKYO<\/span><\/span>, Oct. 16, 2025<\/span><\/span> \/PRNewswire\/ — A.D.A.M. Innovations<\/a>, Japan’s<\/span> leading private genetic testing company, and SOPHiA GENETICS<\/a>\u00a0(Nasdaq: SOPH), an AI technology company pioneering data-driven medicine,\u00a0today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy companion diagnostic aimed at advancing personalized and precision cancer care in Japan<\/span>.<\/p>\n

As a market leader for genetic testing in Japan<\/span> with a high-throughput laboratory located in central Tokyo<\/span>, A.D.A.M. Innovations\u00a0has served the Japanese population for over 20 years and completed over 2.8 million genomic tests to-date. A.D.A.M. Innovations\u00a0will continue its legacy of bringing global innovations to Japan<\/span> by adopting the AI-powered SOPHiA DDM\u2122 Platform to advance personalized cancer testing across the country.<\/p>\n

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS\u00ae powered with SOPHiA DDMTM<\/sup>. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in-house, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research.<\/p>\n

As part of the partnership, the companies also aim to develop a liquid biopsy companion diagnostic (CDx) test in Japan<\/span>. By developing the application into a CDx, more patients can gain access to the benefits of the high-quality tumor profiling test, advancing personalized healthcare at scale. The offering will also provide pharmaceutical partners with a powerful new tool to accelerate drug development and market access in Japan<\/span>. The companies will collaborate across all steps of the development process, with A.D.A.M. Innovations leveraging its deep clinical and regulatory expertise to support regulatory submissions in Japan<\/span>.<\/p>\n

“Making precision oncology more accessible to patients in Japan<\/span> is a significant milestone,” said Ross Muken<\/span>, President, SOPHiA GENETICS<\/span>. “By combining A.D.A.M. Innovations’ strong clinical expertise and local presence with the global reach of the SOPHiA DDM\u2122 Platform,\u00a0we can drive the nationwide adoption of data-driven medicine, advancing both clinical research and the delivery of personalized oncology care.”<\/p>\n

“For over two decades, we have supported academic, research and medical institutions with advanced clinical genomic testing,” commented Michel Mommejat, President of A.D.A.M. Innovations. “Through our partnership with SOPHiA GENETICS and its AI-driven platform, we are taking a major step forward in accelerating precision oncology across Japan<\/span>. Testing locally enables faster turnaround times, reduces costs, enhances patient care, and supports global CDx deployments.”<\/p>\n

The collaboration was formally announced from the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin<\/span>. The announcement underscores both companies’ shared commitment to advancing data-driven and liquid biopsy-based solutions for cancer care in Japan<\/span>. Learn more by connecting with SOPHiA GENETICS and A.D.A.M. Innovations\u00a0at ESMO booth #2039 from October 17-21, 2025<\/span>.<\/p>\n

For more information on SOPHiA GENETICS, visit\u00a0SOPHiAGENETICS.COM<\/a>, or connect on LinkedIn<\/a>.\u00a0<\/p>\n

For more information on A.D.A.M. Innovations, visit\u00a0ADAM-INNOVATIONS.COM<\/a>\u00a0or connect on LinkedIn<\/a>.\u00a0<\/p>\n

About SOPHiA GENETICS<\/b> \u00a0
SOPHiA GENETICS (Nasdaq: SOPH) is a\u00a0cloud-native healthcare technology\u00a0company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients\u00a0with cancer and rare disorders\u00a0across the globe. It is the creator of the SOPHiA DDM\u2122 Platform, which\u00a0analyzes complex genomic and multimodal data\u00a0and generates\u00a0real-time, actionable insights\u00a0for a broad global network of hospital, laboratory, and biopharma institutions.\u00a0\u00a0For more information, visit\u00a0SOPHiAGENETICS.COM<\/a> and connect with us on\u00a0LinkedIn<\/a>.\u00a0<\/p>\n

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com<\/a> to obtain the appropriate product information for your country of residence.<\/i>\u00a0<\/p>\n

SOPHiA GENETICS Forward-Looking Statements:\u00a0<\/i><\/b>
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/i>\u00a0<\/p>\n

About <\/b>A.D.A.M. Innovations Co.
<\/b>Founded in 2004 in Tokyo<\/span>, A.D.A.M. Innovations (currently operating as Genesis Healthcare Co.) is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning clinical diagnostics, consumer genetics, and AI-driven R&D data platforms. To date, it has conducted more than 2.8 million genetic tests and maintains the largest R&D genomic database of the Japanese population. The company’s name will change to A.D.A.M. Innovations Co. effective November 1, 2025<\/span>.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ROLLE, Switzerland\u00a0and TOKYO<\/span><\/span>, Oct. 16, 2025<\/span><\/span> \/PRNewswire\/ — A.D.A.M. Innovations<\/a>, Japan’s<\/span> leading private genetic testing company, and SOPHiA GENETICS<\/a>\u00a0(Nasdaq: SOPH), an AI technology company pioneering data-driven medicine,\u00a0today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy companion diagnostic aimed at advancing personalized and precision cancer care in Japan<\/span>.<\/p>\n

As a market leader for genetic testing in Japan<\/span> with a high-throughput laboratory located in central Tokyo<\/span>, A.D.A.M. Innovations\u00a0has served the Japanese population for over 20 years and completed over 2.8 million genomic tests to-date. A.D.A.M. Innovations\u00a0will continue its legacy of bringing global innovations to Japan<\/span> by adopting the AI-powered SOPHiA DDM\u2122 Platform to advance personalized cancer testing across the country.<\/p>\n

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS\u00ae powered with SOPHiA DDMTM<\/sup>. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in-house, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research.<\/p>\n

As part of the partnership, the companies also aim to develop a liquid biopsy companion diagnostic (CDx) test in Japan<\/span>. By developing the application into a CDx, more patients can gain access to the benefits of the high-quality tumor profiling test, advancing personalized healthcare at scale. The offering will also provide pharmaceutical partners with a powerful new tool to accelerate drug development and market access in Japan<\/span>. The companies will collaborate across all steps of the development process, with A.D.A.M. Innovations leveraging its deep clinical and regulatory expertise to support regulatory submissions in Japan<\/span>.<\/p>\n

“Making precision oncology more accessible to patients in Japan<\/span> is a significant milestone,” said Ross Muken<\/span>, President, SOPHiA GENETICS<\/span>. “By combining A.D.A.M. Innovations’ strong clinical expertise and local presence with the global reach of the SOPHiA DDM\u2122 Platform,\u00a0we can drive the nationwide adoption of data-driven medicine, advancing both clinical research and the delivery of personalized oncology care.”<\/p>\n

“For over two decades, we have supported academic, research and medical institutions with advanced clinical genomic testing,” commented Michel Mommejat, President of A.D.A.M. Innovations. “Through our partnership with SOPHiA GENETICS and its AI-driven platform, we are taking a major step forward in accelerating precision oncology across Japan<\/span>. Testing locally enables faster turnaround times, reduces costs, enhances patient care, and supports global CDx deployments.”<\/p>\n

The collaboration was formally announced from the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin<\/span>. The announcement underscores both companies’ shared commitment to advancing data-driven and liquid biopsy-based solutions for cancer care in Japan<\/span>. Learn more by connecting with SOPHiA GENETICS and A.D.A.M. Innovations\u00a0at ESMO booth #2039 from October 17-21, 2025<\/span>.<\/p>\n

For more information on SOPHiA GENETICS, visit\u00a0SOPHiAGENETICS.COM<\/a>, or connect on LinkedIn<\/a>.\u00a0<\/p>\n

For more information on A.D.A.M. Innovations, visit\u00a0ADAM-INNOVATIONS.COM<\/a>\u00a0or connect on LinkedIn<\/a>.\u00a0<\/p>\n

About SOPHiA GENETICS<\/b> \u00a0
SOPHiA GENETICS (Nasdaq: SOPH) is a\u00a0cloud-native healthcare technology\u00a0company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients\u00a0with cancer and rare disorders\u00a0across the globe. It is the creator of the SOPHiA DDM\u2122 Platform, which\u00a0analyzes complex genomic and multimodal data\u00a0and generates\u00a0real-time, actionable insights\u00a0for a broad global network of hospital, laboratory, and biopharma institutions.\u00a0\u00a0For more information, visit\u00a0SOPHiAGENETICS.COM<\/a> and connect with us on\u00a0LinkedIn<\/a>.\u00a0<\/p>\n

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com<\/a> to obtain the appropriate product information for your country of residence.<\/i>\u00a0<\/p>\n

SOPHiA GENETICS Forward-Looking Statements:\u00a0<\/i><\/b>
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/i>\u00a0<\/p>\n

About <\/b>A.D.A.M. Innovations Co.
<\/b>Founded in 2004 in Tokyo<\/span>, A.D.A.M. Innovations (currently operating as Genesis Healthcare Co.) is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning clinical diagnostics, consumer genetics, and AI-driven R&D data platforms. To date, it has conducted more than 2.8 million genetic tests and maintains the largest R&D genomic database of the Japanese population. The company’s name will change to A.D.A.M. Innovations Co. effective November 1, 2025<\/span>.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-36306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36306"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36306\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}